Interleukin-34 Mediates Cross-Talk Between Stromal Cells and Immune Cells in the Gut

Giovanni Monteleone1,2*, Eleonora Franzè1, Edoardo Troncone1,2*, Claudia Maresca1 and Irene Mara fi1,2*

1 Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy, 2 *Gastroenterology Unit, Policlinico Tor Vergata, Rome, Italy

Initially known as a cytokine produced by and regulating the function of monocytes and macrophages, interleukin-34 (IL-34) can be synthesized by many cell types and interacts with receptors expressed by multiple immune and non-immune cells. IL-34 is constitutively expressed in the healthy human small intestine and colon and its production is markedly increased in damaged gut of patients with Crohn’s disease and patients with ulcerative colitis, the main forms of chronic inflammatory bowel diseases (IBD) in human beings. Circumstantial evidence suggests that, in these pathologies, IL-34 plays a crucial role in mediating cross-talk between immune cells and stromal cells, thereby promoting activation of signalling pathways, which amplify the ongoing mucosal inflammation as well as production of fibrogenic molecules. In this article, we summarize the available data supporting the multiple effects of IL-34 in human IBD with particular attention to the role of the cytokine in immune and stromal cell interactions.

Keywords: cytokines, Crohn’s disease, ulcerative colitis, mucosal inflammation, intestinal fibrosis, M-CSF1

INTRODUCTION

Crohn’s disease (CD) and ulcerative colitis (UC) are the main forms of chronic inflammatory bowel diseases (IBD) in human beings (1–3). These pathologies are characterized by various degrees of mucosal damage and tissue remodelling, which favour the development of ulcers, strictures and fistulae, and local complications (1, 2). The aetiology of both CD and UC remains unknown, but a large body of evidence suggests that both diseases are due to interaction among multiple genetic, environmental and microbial factors, which eventually triggers and sustains an excessive immune reaction within the intestinal wall direct against components of the luminal flora (4, 5).

In inflamed gut of IBD patients, there is massive presence of immune cells (e.g. neutrophils, T and B lymphocytes, natural killer (T) cells and CD14+ monocytes), which are continuously recruited from the peripheral blood (6). These cells synthesize huge amounts of cytokines that can trigger inflammatory signals in both immune and non-immune cells, thus contributing to expand the pathologic process (7). Consistent with this is the demonstration that blockade of effector cytokines, such as interleukin (IL)-12/IL-23 and tumor necrosis factor (TNF), helps...
attenuate the detrimental responses in the gut of IBD patients (8–10). However, some patients are primarily or secondarily resistant to such drugs or develop drug-related adverse events, thus suggesting the necessity of additional therapeutic agents (11).

Initially known as a cytokine produced by monocytes and macrophages, IL-34 can be synthesized by additional cell types, including epithelial cells, macrophages, endothelial cells, fibroblasts, neurons, hepatocytes and, and is constitutively expressed in many adult human organs, such as heart, brain, liver, spleen, thymus, testis, ovary, prostate, small intestine, and colon (12–16).

IL-34 is a powerful regulator of myeloid cell differentiation and behaviour. In addition, IL-34 mediates the function of many other cell types with the downstream effect of either amplifying or limiting immune-inflammatory responses in some organs/tissues (17–24).

In this article, we review the available data supporting the multiple effects of IL-34 in human IBD with particular attention to the role of the cytokine in promoting stromal and immune cell interactions. We discuss also similarities and differences in the roles of IL-34 and macrophage colony-stimulating factor (M-CSF-1) in the control of gut homeostasis and inflammation as these two molecules bind the same receptor, namely macrophage colony-stimulating factor receptor (M-CSF-1R) (12).

INTERLEUKIN 34 SIGNALLING

Although IL-34 and M-CSF-1 bind to overlapping regions of M-CSF-1R (25) they can activate distinct signalling pathways depending on the hydrophobic/hydrophilic interaction of each cytokine with M-CSF1-R (26–30). IL-34 binds to M-CSF-1-R by hydrophobic interaction while M-CSF-1 binding to M-CSF-1R is mediated by a hydrophilic interaction. Hydrophobic interactions are more stable than hydrophilic ones and, therefore, IL-34 induces a stronger and faster auto-phosphorylation of tyrosine residues of the intracellular domain of M-CSF-1R, as well as of FAK, MAP Kinases and other downstream targets as compared to M-CSF-1 (30). In human monocytes, IL-34 and M-CSF-1 are equally able to promote phosphorylation of AKT, ERK1/2, AMPK and ULK1 (31, 32). These differences in intracellular pathways help explain the non-redundant roles of the two cytokines on some macrophage functions, as well as the fact that IL-34 activity on monocytes is independent of M-CSF-1 (12). In this context, for instance, it has been demonstrated that IL-34-differentiated macrophages exhibit over-expression of eotaxin 2 and HLA-DR and down-regulation of CD54 and MCP-1 as compared to M-CSF-1-stimulated macrophages (30). Moreover, M-CSF-1-treated macrophages have enhanced capacity for bacteria phagocytosis as compared to IL-34-derived macrophages (33). IL-34-derived macrophages and M-CSF-1-derived macrophages produce similar amount of IL-10 but low level of IL-12 (34). However, upon inflammatory macrophage type 1 (M1) polarization (i.e. LPS + IFNγ), IL-34-treated macrophages express higher IL-10 and CXCL11 levels than M-CSF-1-stimulated macrophages, while in response to regulatory M2 polarization (i.e. IL-4), IL-34-treated macrophages produce more chemokine ligand (CCL) 17 and CCL22 and less IL-10 than M-CSF-1-differentiated macrophages (31).

Unlike M-CSF-1, which only interacts with M-CSF-1R, IL-34 can bind to additional receptors, such as receptor-type protein-tyrosine phosphatase zeta (PTP-ζ), a chondroitin sulfate proteoglycan primarily expressed on neuronal progenitors and glial cells, kidney tubular cells, monocytes and B cells, and syndecan-1 (also known as CD138), a heparan sulfate and/or chondroitin sulfate proteoglycan prevalently expressed by epithelial cells and able to bind many other ligands (i.e. proteins of the extracellular matrix, cytokines and growth factors (30, 31)).

During embryogenesis as well as at the adult stage, IL-34 and M-CSF-1 have distinct expression patterns and there is evidence that M-CSF-1 exerts a more systemic function while IL-34 has tissue-restricted actions. Studies in knockout mice showed that loss of M-CSF-1R or M-CSF-1 led to a more severe phenotype, with severe deficiency in mature macrophages and osteoclasts, reduced lifespan, growth, fertility as compared to IL-34-deficient animals, probably reflecting the major involvement of M-CSF-1 in the development of osteoclasts, myeloid cells and in the production of IGF-1, the activity of which is essential to growth and organ maturity (14, 15, 35–38). However, M-CSF-1R-deficient animals exhibit a more harmful phenotype than M-CSF-1-deficient mice, indicating a contribution of IL-34 in such mechanisms.

ROLE OF M-CSF-1R-DRIVEN SIGNALLING IN THE CONTROL OF GUT HOMEOSTASIS

Analysis of M-CSF-1R in the gut revealed its expression throughout the crypts in both the mouse and human colon, to the crypt base (i.e. Paneth cells) of the small intestine as well as on lamina propria myeloid cells and stromal cells (21, 39, 40). However, data from Sehgal and colleagues contradicted this view and showed that M-CSF-1R mRNA expression is restricted to macrophages, which are intimately associated with the crypt epithelium, and is undetectable in Paneth cells (41). The reasons for the discrepancy between these studies are uncertain. Regardless of whether Paneth cells express M-CSF-1R, studies in mice lacking either M-CSF-1R- or M-CSF-1 clearly indicate a prominent role of M-CSF-1R in the control of epithelial cell differentiation. Specifically, M-CSF-1R loss impeded the development of M cells in Peyer’s patches, and associated with deficits in small intestinal enterocytes and enteroendocrine cells, excessive goblet cell production, and reduced crypt proliferative capacity and stem cell niche maintenance in the small intestine (42). Consistently, loss of either M-CSF-1R or M-CSF-1 resulted in defects in enterocytes and enteroendocrine cell fate, with excessive goblet cell production and reduced cell proliferation in the colon (39). These data are in line with the in
In vitro demonstration that M-CSF-1 enhances murine fetal and prenatal colon cell proliferation (40).

In order to assess the M-CSF1- and IL-34-mediated regulation of macrophage homeostasis, Lin and colleagues treated C57BL6 mice with highly selective antibodies against M-CSF-1 or IL-34, either separately or in combination for 4 weeks, and then evaluated various tissues by immunostaining using F4/80 antibody to identify resident macrophages. Treatment with anti-M-CSF-1 or anti-M-CSF-1-anti-IL-34 but not with anti-IL-34 alone reduced the number of intestinal macrophages. Although these findings do not help ascertain whether the effect of the IL-34/M-CSF-1 blockers on intestinal macrophage survival is either direct or indirect, they clearly indicate a dominant role of M-CSF-1 versus IL-34 in the control of macrophage homeostasis in the gut (43). Expression of M-CSF-1R on macrophages seems to be also crucial in the cross-talk between macrophages and intestinal epithelial cells. Indeed, it has been demonstrated that intestinal crypt-associated macrophages are required to maintain the crypts in the small intestine as depletion of macrophages by prolonged M-CSF-1R blockade inhibited Paneth cell differentiation and led to a reduction of Lgr5+ intestinal stem cells (41). The factors produced by the crypt-associated M-CSF-1R-expressing macrophages, which support Paneth cell differentiation, remain unknown.

We and others have shown that human intestinal stromal cells express M-CSF-1R and produce both M-CSF-1 and IL-34 (18, 44). By using a 3D human organotypic colorectal cancer model, Stadler and colleagues showed that stromal cell-derived M-CSF-1 can target M-CSF-1R on myeloid cells and positively regulate the macrophage number in the cultures as well as expression of chemokines and CD163 (44). The phenotype of M-CSF-1-stimulated macrophages resembles that of normal intestinal resident macrophages, which are highly positive for CD163, CD163L1 and CD206 and have the ability to promote epithelial barrier integrity and activate counter-regulatory pathways (45, 46). Overall, these findings support the view that M-CSF-1R signalling, by promoting the link between macrophages and epithelial cells/stromal cells, contributes to maintain gut homeostasis.

**IL-34 IS OVER-EXPRESSED IN THE GUT OF IBD PATIENTS AND REGULATES INFLAMMATORY CYTOKINE AND CHEMOKINE PRODUCTION**

As pointed out above, IBD tissue is massively infiltrated with activated monocytes/macrophages and dendritic cells, which have the ability to respond to bacterial products by producing a large array of inflammatory molecules and tissue-degrading enzymes (4). Therefore, identifying the key regulators of the function of such cells could help advance our understanding about the basic mechanisms underlying the IBD-associated pathogenic process. Analysis of IL-34 RNA and protein expression in paired biopsy samples taken from involved and uninvolved mucosal areas of IBD patients and normal controls showed the predominant induction of the cytokine in inflamed gut of both CD patients and UC patients as compared to uninvaded gut of the same patients and healthy intestine (23). Accordingly, data from the IBD Transcriptome and Metatranscriptome Meta-Analysis (TaMMA) framework, a comprehensive survey of publicly available IBD RNA-sequencing datasets, confirmed the increased IL-34 gene expression in ileal CD compared to controls (47). Similarly, M-CSF-1 RNA transcripts were found to be elevated in inflamed gut of CD patients and UC patients compared to non-IBD control diverticulitis and normal tissues (43). Additionally, M-CSF-1 gene sets were enriched in the colonic mucosal transcriptomes of CD patients and particularly in those who did not respond to TNF blockers (48).

Up-regulation of both IL-34 and M-CSF-1 was documented in the colons of mice with dextran sulfate sodium (DSS)-colitis (49). Analysis of these two cytokines in gut samples of TNFaΔRE mice, which show some immunological similarities with CD (50), showed that M-CSF1 was increased in the ileum and cecum, whereas IL34 was elevated primarily in the jejunum and ileum (43).

Immunohistochemical analysis of human gut mucosal samples showed that, in IBD, IL-34 was over-produced not only by lamina propria myeloid cells but also by stromal cells and epithelial cells (23). These findings raised the possibility that, in IBD, IL-34 production is positively regulated by molecules synthesized and/or acting within the inflamed gut. Indeed, stimulation of unfractoned lamina propria mononuclear cells (LPMC) isolated from normal colonic samples with TNF, a cytokine over-produced in both CD and UC (4), increased IL-34 production while blockade of TNF with a neutralizing antibody in IBD LPMC cultures and ex vivo mucosal explants taken from IBD patients reduced IL-34 synthesis. Additionally, several toll-like receptor ligands, such as peptidoglycan, Poly (I:C) and CpG stimulated IL-34 production in LPMC (23) (Figure 1). Functionally, IL-34 triggered ERK1/2 activation in normal colonic LPMC thus enhancing IL-6 and TNF production. Consistently, blockade of IL-34 with a neutralizing antibody reduced TNF and IL-6 expression in IBD mucosal explants. Overall, these findings fit with the demonstration that IL-34 has significant action in regulating immune responses through a complex signaling network, involving not only MAP kinases but also nuclear factor-kappa B, a crucial molecule for activation of inflammatory signaling processes (23) (Figure 1). Indeed, IL-34 has been reported to amplify production of pro-inflammatory cytokines, chemokines, and tissue-damaging proteases by various immune and non-immune cell types (51) and up-regulation of the cytokine has been seen in pathologies characterized by accumulation of pro-inflammatory monocytes in inflamed sites (52).

Studies in other systems have also shown that, under specific circumstances, IL-34 can act as a regulatory molecule and this relies in part on the ability of the cytokine to induce differentiation of monocytes to type 2 macrophages, which
possess an immunosuppressive effect on NK and T cell responses (34, 53). However, treatment of intestinal LPMC with IL-34 did not change expression of CD206 and Arginase1, two markers of type 2 macrophages, thus suggesting that IL-34-driven induction of inflammatory cytokines in the gut is not secondary to shifts in the differentiation/development of monocyte/macrophages (23).

Although no study has yet evaluated the action of IL-34 on the differentiation/function of T cells in IBD, it is noteworthy that IL-34-primed macrophages constitutively express membrane-type IL-1α, which stimulates differentiation of memory Th17 cells (54), a subset of CD4+ T cells that infiltrates massively inflamed gut in IBD and contributes to mucosal injury seen in mice with experimental colitis (55, 56).

In IBD, the expansion of the pathogenic inflammatory response is partly mediated by recruitment of immune cells from the circulation to inflamed mucosa, as a result of interaction between integrins and adhesion molecules and action of multiple chemokines. Chemokines are mainly secreted by epithelial cells in response to inflammatory stimuli (e.g. cytokines) derived from immune cells and stromal cells (6, 57). IL-34 could be one these cytokines, as recent studies indicate that gut epithelial cells are a potential target of IL-34. Indeed, by immunohistochemistry, we showed that in the normal colon, epithelial cells constitutively expressed M-CSFR-1 even though M-CSFR-1-producing cells were more frequent in both the epithelial and lamina propria compartments of IBD patients (23). Stimulation of gut epithelial cells with IL-34, but not M-CSF-1, enhanced secretion of the CCL20 (21). Consistently, neutralization of IL-34 in ex vivo mucosal explants taken from IBD patients with a blocking IL-34 reduced CCL20 secretion (Figure 1). These findings could be pathogenetically relevant as CCL20 is highly produced by IBD epithelial cells and supposed to contribute to the recruitment of immune cells from the circulation to inflamed intestine (58).

Functional studies aimed at evaluating the effect of M-CSF-1 and/or IL-34 neutralization in murine models of colitis showed that pre-treatment of mice with both anti-M-CSF1 and anti-IL-34 one day prior to DSS challenge reduced the number of intestinal macrophages, the expression of inflammatory cytokines and limited damage as compared to mice treated with control antibody. Single treatment with either anti-M-CSF1 or anti-IL-34 was only marginally beneficial. Similarly, dual inhibition of IL-34 and M-CSF-1 improved body weight and reduced gut inflammation in TNF\textsuperscript{ARE} mice while single monotherapies were not effective. Finally, simultaneous blockade of IL-34 and M-CSF-1 reduced intestinal inflammation developing in mice with IL-10 deficiency (43). Consistently, mice lacking M-CSF-1R were protected from DSS-induced colitis as compared to wild-type mice (39). Administration of JNJ-40346527, a small molecule inhibitor of M-CSF-1R, to mice with T-cell transfer colitis attenuated clinical disease scores and reduced inflammatory gene expression (48).

Altogether, these observations are consistent with the pathologic role of IL-34 and M-CSF-1 in the gut and indicate that neutralization of both IL-34 and M-CSF-1 can help dampen the local tissue-damaging inflammatory response.

**INTERLEUKIN-34 ENHANCES THE PRO-FIBROGENIC PROPERTIES OF GUT STROMAL CELLS**

IBD course can be complicated by fibrosis and development of strictures. These complications are seen more frequently in

![FIGURE 1](https://example.com/figure1.png)
patients with ileal CD, but fibrosis can be also found in colonic CD and UC (59, 60). The basic mechanisms underlying fibrosis are not yet fully understood, even though accumulating evidence supports the hypothesis that fibrosis results from the chronic activity of immune-inflammatory cells, which stimulate excessive deposition of extracellular matrix (ECM) proteins by stromal cells (e.g. fibroblasts) (61, 62). The activated stromal cells secrete in turn several pro-fibrogenic cytokines [e.g. TGF-β, interleukin (IL)-1β, and IL-6], with the downstream effect of enhancing ECM deposition and amplifying the fibrotic process (59, 63–66). Indeed, administration of compounds inhibiting the function of such profibrotic cytokines to mice prevented or cured colitis-induced intestinal fibrosis (67–71).

Since IL-34 has been involved in the control of lung and joint fibroblasts (72, 73), we examined whether IL-34 regulates gut stromal cell function. The initial studies showed that M-CSFR-1 expression was markedly increased in gut samples taken from CD patients with fibrostrictures as compared to samples taken from CD patients with inflammatory phenotype and normal controls and immunohistochemical analysis of such samples showed that stromal cells were highly positive for the receptor (18). We also showed that stromal cells isolated from fibrostricturing specimens of CD patients and expressing typical markers of myofibroblasts, such as vimentin, α-SMA, and CD90, responded in vitro to IL-34 by enhancing COL1A1 and COL3A1 expression and secretion of soluble forms of collagen. The positive effect of IL-34 on collagen synthesis was abrogated by a pharmacological inhibitor of p38 MAP kinase. In line with this was also the demonstration that IL-34 RNA and protein expression was up-regulated in fibrotic samples of CD patients as compared to both inflamed and normal controls and, in fibrostricturing CD tissues, stromal cells were largely positive for IL-34. Knockdown of IL-34 with a specific antisense oligonucleotide in CD myofibroblasts isolated from fibrostricturing specimens reduced both p38 MAP kinase activation, COL1A1 and COL3A1 expression, and secretion of collagen in the culture supernatants (18). It is thus plausible that intestinal myofibroblasts are both a cell source and a target of IL-34. This fits also with recent studies showing that IL-34 stimulates migration and proliferation of synovial fibroblasts isolated from patients with rheumatoid arthritis (74, 75) and enhances production of inflammatory cytokines by lung fibroblasts (72). The potential involvement of IL-34 in the amplification of fibrotic processes is supported by studies in other disorders. For example, IL-34 stimulates liver macrophages to acquire profibrotic properties, and in chronically hepatitis C virus (HCV)-infected patients, serum level of IL-34 well correlate with the fibrosis stage (16). IL-34 is highly produced in patients with diffuse cutaneous systemic sclerosis, and the serum levels of the cytokine in such patients correlate positively with fibrotic score on chest computed tomography (76). Finally, in patients with non-alcoholic fatty liver disease, serum IL-34 level increases with the progression of fibrosis (77).

**DISCUSSION**

Our understanding about the involvement of IL-34 in IBD pathogenesis is still limited, but in recent years, some studies have highlighted the multiple effects of the cytokine on the ongoing mucosal inflammation in these disorders. It is now evident that IL-34 has many cell sources in the gut and signalling pathways activated by locally-produced cytokines and/or bacterial products sustain IL-34 production. At the same time, the main IL-34 receptor, namely M-CSFR-1, is simultaneously expressed by immune cells and non-immune cells, such as...
epithelial cells and stromal cells (18, 23). This helps delineate a scenario, in which IL-34, by acting via a paracrine or autocrine manner, either alone or in combination with M-CSF-1, can mediate the cross-talk among different mucosal cell types in IBD (Figure 2). Considering that IL-34 protein expression is barely detectable in the human healthy gut and its production is pronounced in inflamed gut of both CD patients and UC patients, it is conceivable that IL-34 may have a role in promoting tissue destruction. This hypothesis is supported by in vitro observations indicating that IL-34 triggers signals that, in the gut, amplify production of inflammatory cytokines and chemokine and pro-fibrogenic molecules (18, 21, 23). Nonetheless, very little is known about the in vivo function of the cytokine. Recent studies in wild-type mice with colitis treated with neutralizing antibodies indicate that depending on the disease, single or dual blockade of M-CSF-1 and IL-34 is needed for inhibiting mucosal inflammation consistent with the concordant tissue-specific expression of both cytokines in inflamed gut (43). Nonetheless, further studies are necessary to explore the role of both IL-34 and M-CSF-1 in additional models of colitis and colitis-associated fibrosis as we cannot exclude the possibility that selective inhibition of IL-34 may either not be adequate to control gut pathology or paradoxically exacerbate the disease. Indeed, it has been reported that IL-34 not only induces immunosuppressive macrophage phenotypes but also enhances in vitro suppressive function of CD4+ and CD8+ regulatory T cells (Tregs) (61). IL-34 can be secreted by FOXP3-expressing CD4+ and CD8+ Tregs in humans and CD8+CD45RClow/- Tregs in rats (61) and, at least in vitro, it is more efficient at inducing FOXP3-expressing Tregs than M-CSF-1 and these cells efficiently control acute graft-vs.-host disease in vivo in a model of immune humanized immunodeficient mice (62). As discussed in this article, IL-34, but not M-CSF-1, also engages other receptors, the distribution of which in inflamed gut remains poorly characterized. At the same time, there is little knowledge about the distinction between the functional effects of such receptors and those mediated by M-CSF-1R. All these issues make the biology of IL-34 in IBD complex and far from being clearly defined. The future work will provide the necessary insight into whether IL-34 can be exploited as a therapeutic target for attenuating the detrimental immune and fibrotic responses in patients with IBD.

REFERENCES

1. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s Disease. *Lancet* (2017) 389(10080):1741–55. doi: 10.1016/S0140-6736(16)31711-1
2. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative Colitis. *Lancet* (2017) 389(10080):1756–70. doi: 10.1016/S0140-6736(16)32126-2
3. Abraham C, Cho JH. Inflammatory Bowel Disease. *N Engl J Med* (2009) 361(21):2066–78. doi:10.1056/NEJMr0804647
4. Macdonald TT, Monteleone G. Immunology, Inflammation, and Allergy in the Gut. *Science* (2005) 307(5717):1920–5. doi:10.1126/science.1106442
5. Digby-Gell JL, Atreya R, Monteleone G, Powell N. Interrogating Host Immunity to Predict Treatment Response in Inflammatory Bowel Disease. *Nat Rev Gastroenterol Hepatol* (2019) 17:9–20. doi:10.1038/s41575-019-0228-5
6. Zandler S, Becker E, Schulze LL, Neurath MF. Immune Cell Trafficking and Retention in Inflammatory Bowel Disease: Mechanistic Insights and Therapeutic Advances. *Gut* (2019) 68(9):1688–700. doi:10.1136/gutjnl-2018-317977
7. Stober W, Fuss J. Proinflammatory Cytokines in the Pathogenesis of Inflammatory Bowel Diseases. *Gastroenterology* (2011) 140(6):1756–67. doi:10.1053/j.gastro.2011.02.016
8. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Braakman T, et al. A Short-Term Study of Chimeric Monoclonal Antibody CA2 to Tumor Necrosis Factor Alpha for Crohn’s Disease. Crohn’s Disease CA2 Study Group. *N Engl J Med* (1997) 337(15):1029–35. doi:10.1056/NEJM199710093371502
9. Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, et al. Ustekinumab Induction and Maintenance Therapy in Refractory Crohn’s Disease. *N Engl J Med* (2012) 367(16):1519–28. doi:10.1056/NEJMoa1203572
10. Marafini I, Sedda S, Dinello V, Monteleone G. Inflammatory Cytokines: From Discoveries to Therapies in IBD. *Expert Opin Biol Ther* (2019) 19(11):1207–17. doi:10.1080/14712598.2019.1652267

AUTHORS CONTRIBUTIONS

GM conceptualization, manuscript preparation, supervision; EF, ET, CM literature search, writing initial draft; IM manuscript preparation, critical revision. All authors contributed to the article and approved the submitted version.

11. Dalal SR, Cohen RD. What to Do When Biologic Agents Are Not Working in Inflammatory Bowel Disease Patients. *Gastroenterol Hepatol* (2015) 11(10):657–65.
12. Lin H, Lee E, Hestir K, Lee C, Huang M, Bosch E, et al. Discovery of a Cytokine and Its Receptor by Functional Screening of the Extracellular Proteome. *Science* (2008) 320(5877):807–11. doi:10.1126/science.1154370
13. Baud'huin M, Renault R, Charrier C, Riet A, Moreau A, Brion R, et al. Interleukin-34 Is Expressed by Giant Cell Tumours of Bone and Plays a Key Role in Rank-L-Induced Osteoclastogenesis. *J Pathol* (2010) 221(1):77–86. doi:10.1002/path.2684
14. Greter M, Lielos I, Pelczar P, Hoffel G, Price J, Leboeuf M, et al. Stromal-Derived Interleukin-34 Controls the Development and Maintenance of Langerhans Cells and the Maintenance of Microglia. *Immunity* (2012) 37(6):1050–60. doi:10.1016/j.immuni.2012.11.001
15. Wang Y, Szwedo KJ, Vermi W, Gilfillan S, Rossini C, Cella M, et al. IL-34 Is a Tissue-Restricted Ligand of Csf1r Required for the Development of Langerhans Cells and Microglia. *Nat Immunol* (2012) 13(8):753–60. doi:10.1038/ni.2360
16. Preissler L, Miot C, Le Guillou-Guillemette H, Beaumont E, Foucher ED, Garo E, et al. Macrophage Colony-Stimulating Factor Overexpressed in Hepatitis C Virus Fibrosis and Induce Profibrotic Macrophages That Mediate Collagen Synthesis by Hepatic Stellate Cells. *Hepatology* (2014) 60(6):1879–90. doi:10.1002/hep.27328
17. Franze E, Di Grazia A, Sica GS, Biancone L, Laudisi F, Monteleone G. Interleukin-34 Enhances the Tumor Promoting Function of Colorectal Cancer-Associated Fibroblasts. *Cancers* (2020) 12(12):3537. doi:10.3390/cancers12123537
18. Franze E, Dinello V, Laudisi F, Di Grazia A, Di Fusco D, Colantoni A, et al. Interleukin-34 Stimulates Gut Fibroblasts to Produce Collagen Synthesis. *J Crohns Colitis* (2020) 14(10):1436–45. doi:10.1093/ijccjm/jjaa073
19. Franze E, Dinello V, Rizzo A, Di Giovangiuilio M, Bevivino G, Stolfi C, et al. Interleukin-34 Sustains Pro-Tumorigenic Signals in Colon Cancer Tissue. *OncoTarget* (2018) 9(3):3432–45. doi:10.18632/oncotarget.23289
69. Li G, Ren J, Hu Q, Deng Y, Chen G, Guo K, et al. Oral Pirfenidone Protects
70. Fichtner-Feigl S, Young CA, Kitani A, Geissler EK, Schlitt HJ, Strober W. Il-13
71. Johnson LA, Rodansky ES, Haak AJ, Larsen SD, Neubig RR, Higgins PD.
72. Johnson JA, Rodansky ES, Haak AJ, Larsen SD, Neubig RR, Higgins PD.
73. Rieder F, Fiocchi C. Intestinal Fibrosis in Inflammatory Bowel Disease: Progress in Basic and Clinical Science. Curr Opin Gastroenterol (2008) 24(4):462–8. doi: 10.1097/MOG.0b10033282f8b36
74. Zorzi F, Calabrese E, Monteleone G. Pathogenic Aspects and Therapeutic Avenues of Intestinal Fibrosis in Crohn’s Disease. Clin Sci (2015) 129(12):1107–13. doi: 10.1042/CS20150472
75. Rieder F, Fiocchi C. Intestinal Fibrosis in Ibd—a Dynamic, Multifactorial Process. Nat Rev Gastroenterol Hepatol (2009) 6(4):228–35. doi: 10.1038/nrgastro.2009.31
76. Wynn TA. Cellular and Molecular Mechanisms of Fibrosis. J Pathol (2008) 214(2):199–210. doi: 10.1002/path.2277
77. Rieder F, Fiocchi C. Intestinal Fibrosis in Inflammatory Bowel Disease - Current Knowledge and Future Perspectives. J Crohns Colitis (2008) 2(4):279–90. doi: 10.1016/j.jcrohns.2008.05.009
78. Fiocchi C, Lund PK. Themes in Fibrosis and Gastrointestinal Inflammation. Am J Physiol Gastrointest Liver Physiol (2011) 300(5):G677–83. doi: 10.1152/ajpgi.00104.2011
79. Kendall RT, Feghali-Bostwick CA. Fibroblasts in Fibrosis: Novel Roles and Mediators. Front Pharmacol (2014) 5:123. doi: 10.3389/fphar.2014.00123
80. Lawrance IC, Rogler G, Bamias G, Breynaert C, Florholmen J, Pellino G, et al. Cellular and Molecular Mediators of Intestinal Fibrosis. J Crohns Colitis (2017) 11(12):1491–503. doi: 10.1016/j.jcrohns.2014.09.008
81. Fichtner-Feigl S, Young CA, Kitani A, Geissler EK, Schlitt HJ, Strober W. IL-13 Signaling Via IL-13R Alpha2 Induces Major Downstream Fibrogenic Factors Mediating Fibrosis in Chronic Thbs Colitis. Gastroenterology 2008:135 (6):2003–13, 13 el-7. doi: 10.1053/j.gastro.2008.08.055
82. Johnson LA, Rodansky ES, Haak AJ, Larsen SD, Neubig RR, Higgins PD. Novel Rho/Mrtf/Srf Inhibitors Block Matrix-Stiffness and Tgf-Beta-Induced Fibrogenesis in Human Colonic Myofibroblasts. Inflamm Bowel Dis (2014) 20(1):154–65. doi: 10.1097/MIB.0000437615.98881.31
83. Li G, Ren J, Hu Q, Deng Y, Chen G, Guo K, et al. Oral Pirfenidone Protects Against Fibrosis by Inhibiting Fibroblast Proliferation and Tgf-Beta Signaling in a Murine Colitis Model. Biochem Pharmacol (2016) 117:57–67. doi:10.1016/j.bcp.2016.08.002
84. Imai J, Hozumi K, Sumiyoshi H, Yazawa M, Hirano K, Abe J, et al. Anti-Fibrotic Effects of a Novel Small Compound on the Regulation of Cytokine Production in a Mouse Model of Colorectal Fibrosis. Biochim Biophys Acta (2015) 1851(4):554–60. doi: 10.1016/j.bjba.2015.10.023
85. Specia S, Rousseaux C, Dubuquoy C, Rieder F, Vetuschi A, Sferra R, et al. Novel Ppargamma Modulator Ged-0507-34 Levo Ameliorates Inflammation-Driven Intestinal Fibrosis. Inflamm Bowel Dis (2016) 22(2):279–92. doi: 10.1097/MIB.0000000000001618
86. Zhou J, Sun X, Zhang J, Yang Y, Chen D, Cao J. IL-34 Regulates IL-6 and IL-8 Production in Human Lung Fibroblasts Via Mapk, P3k-Akt, Jak and Nf-kappab Signaling Pathways. Int Immunopharmacol (2018) 61:119–25. doi: 10.1016/j.intimp.2018.05.023
87. Wang B, Ma Z, Wang M, Sun X, Tang Y, Li M, et al. IL-34 Upregulated Th17 Production Through Increased IL-6 Expression by Rheumatoid Fibroblast-Like Synoviocytes. Mediators Inflamm (2017) 2017:1567120. doi: 10.1155/2017/1567120
88. Li X, Lei Y, Gao Z, Wu G, Gao W, Xia L, et al. IL-34 Affects Fibroblast-Like Synoviocyte Proliferation, Apoptosis and Function by Regulating Il-17. Sci Rep (2021) 11(1):16378. doi: 10.1038/s41598-021-95839-1
89. Elkhider A, Wei J, Al-Azab M, Tang Y, Walana W, Li W, et al. IL-34 Modulates Rheumatoid Synovial Fibroblasts Proliferation and Migration Via Erk/Akt Signalling Pathway. Clin Exp Rheumatol (2020) 38(3):479–87.
90. Kuzum A, Yoshizaki A, Toyama S, Fukasawa T, Ebata S, Nakamura K, et al. Serum Interleukin-34 Levels in Patients With Systemic Sclerosis: Clinical Association With Intestinal Lung Disease. J Dermatol (2018) 45(10):1216–20. doi: 10.1111/j.1436-8138.14538
91. Shoji H, Yoshio S, Mano Y, Kumagai F, Sugiyama M, Korenaga M, et al. Interleukin-34 as a Fibroblast-Derived Marker of Liver Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease. Sci Rep (2016) 6:28814. doi: 10.1038/srep28814

Conflict of Interest: GM has served as an advisory board member for ABBVIE. IM has served as a speaker for Janssen.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.